This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Colonoscopy after colorectal cancer

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Follow-up after apparently curative resection

  • start follow-up at a clinic visit 4-6 weeks after potentially curative treatment

  • offer patients regular surveillance with:
    • a minimum of two CTs of the chest, abdomen, and pelvis in the first 3 years and
    • regular serum carcinoembryonic antigen tests (at least every 6 months in the first 3 years) (1)

Consensus guidelines have been developed by the British Society of Gastroenterology, the Association of Coloproctology of Great Britain and Ireland and Public Health England (2)

Key recommendations are that the high-risk criteria for future colorectal cancer (CRC) following polypectomy comprise EITHER:

  • 2 or more premalignant polyps including at least one advanced colorectal polyp (defined as a serrated polyp of at least 10mm in size or containing any grade of dysplasia, or an adenoma of at least 10mm in size or containing high-grade dysplasia);
  • OR
  • 5 or more premalignant polyps


  • start reinvestigation if there is any clinical, radiological or biochemical suspicion of recurrent disease

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.